Latest Boehringer Ingelheim Corporation Stories
RIDGEFIELD, Conn. and INDIANAPOLIS, June 15, 2011 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced Tradjenta(TM) (linagliptin) tablets are now available by prescription in pharmacies across the United States including Walgreens, CVS, Rite Aid and many leading chain and independent pharmacies. The U.S. Food and Drug Administration (FDA) approved TRADJENTA on May 2, 2011 as a prescription medication used along with diet and...
RIDGEFIELD, Conn., May 25 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. will present new phase Ib data at the 2011 American Society of Clinical Oncology (ASCO) annual meeting in Chicago (June 3-7) that indicates combining its investigational therapy afatinib (BIBW 2992) with cetuximab at the maximum tested dose controlled disease in all (n=22) treated epidermal growth factor receptor (EGFR)-mutation positive patients with non-small cell lung cancer (NSCLC) who developed...
RIDGEFIELD, Conn., May 19, 2011 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced that Pradaxa® (dabigatran etexilate mesylate) capsules has received preferred Tier 2 formulary status with all AARP Medicare Part D plans through its pharmacy benefits manager, Prescription Solutions®. The AARP plans, which include AARP Medicare Rx and AARP MedicareComplete from Secure Horizons, provide prescription drug access to nearly 6.8 million Americans and...
RIDGEFIELD, Conn., May 18, 2011 /PRNewswire/ -- Landmark public health campaign DRIVE4COPD announced today that Tim Wright was chosen from more than 150 entries as the winner of the Tune Up for COPD Songwriting Competition. DRIVE4COPD Celebrity Ambassadors Billy Ray Cyrus and Patty Loveless were among the judges for the competition, launched in partnership with the Country Music Association (CMA), which challenged Americans to create a new DRIVE4COPD song to help raise awareness of chronic...
RIDGEFIELD, Conn., May 12, 2011 /PRNewswire/ -- As an actress, Susan Lucci has loved many men in her storied soap opera career, but when her real-life leading man was diagnosed with atrial fibrillation, or AFib, she jumped into action and pledged to learn everything she could about his condition. Now, Lucci and her husband, Helmut Huber, are raising awareness of AFib, a type of irregular heartbeat(1) that may increase a person's risk of stroke nearly five times(2), as program ambassadors...
RIDGEFIELD, Conn. and INDIANAPOLIS, May 2, 2011 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved Tradjenta(TM) (linagliptin) tablets, a prescription medication used along with diet and exercise to lower blood sugar in adults with type 2 diabetes. TRADJENTA can be used as monotherapy or in combination with other commonly prescribed medications for type 2 diabetes --...
RIDGEFIELD, Conn. and INDIANAPOLIS, May 2, 2011 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved Tradjenta(TM) (linagliptin) tablets, a prescription medication used along with diet and exercise to lower blood sugar in adults with type 2 diabetes. TRADJENTA can be used as monotherapy or in combination with other commonly prescribed medications for type 2 diabetes --...
RIDGEFIELD, Conn., April 26, 2011 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that enrollment has commenced at North American sites in its pivotal Phase 3 clinical trial program for BI 201335, the Company's investigational, oral protease inhibitor for the treatment of chronic hepatitis C virus (HCV). Phase 3 trials have begun recruiting to evaluate BI 201335 plus standard-of-care (SOC) in both treatment-naive and -experienced patients with chronic genotype-1...
RIDGEFIELD, Conn., April 4, 2011 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Viramune® XR(TM) (nevirapine) extended-release tablets, a one-pill, once-daily (400 mg) formulation of nevirapine for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults. "With the approval of once-daily VIRAMUNE XR, patients in the U.S. now have the benefit of a new HIV...
RIDGEFIELD, Conn., April 4, 2011 /PRNewswire/ -- Two new retrospective subanalyses of the RE-LY(R) trial, involving Pradaxa(R) (dabigatran etexilate mesylate) capsules, suggested that the reduction in stroke risk achieved with PRADAXA 150mg over warfarin (1) occurred irrespective of CHA2DS2-VASc risk score (2) and the type of non-valvular atrial fibrillation (NVAF) (permanent, persistent and paroxysmal)(3). The results were presented at the American College of Cardiology's 60th Annual...
